|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the role of TLR4 in the pathogenesis of atherosclerosis and vulnerable plaque development.
|
19900676 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic ablation of TLR4 partially reversed atherosclerosis exacerbation in EDA(fl/fl)Apoe(-/-) mice (P<0.05) but had no effect on atherosclerotic lesions in EDA(-/-)Apoe(-/-) mice.
|
26427793 |
2015 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, our data offer an explanation for the comparable effects of IFNα or IFNγ priming on TLR4-induced activation in vascular and immune cells, with important implications in atherosclerosis.
|
31231385 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLR3 and TLR4 as innate immune factors have been proven to play a key role in atherosclerosis disease.
|
26318748 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 4 (TLR-4) is believed to contribute to the initiation and progression of atherosclerosis.
|
15953129 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt5a expression has also been liked to Toll-like receptor-4 (TLR-4), an innate immune receptor implicated in atherosclerosis.
|
18456733 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, there is accumulating evidence for the involvement of TLR4 (Toll-like receptor 4) and its adaptor protein MyD88 (myeloid differentiation primary response 88) in atherosclerosis.
|
31597445 |
2020 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previously, Matrix metalloproteinase-9 (MMP-9), monocyte chemotactic protein-1 (MCP-1) and toll-like receptor 4 (TLR4) were confirmed to play an important role in atherosclerosis and plaque instability.
|
28957799 |
2017 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presence of the Asp299Gly allele of the TLR4 gene does not seem to exert a major influence on the progression of atherosclerosis in patients with FH.
|
14764071 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Observational studies point towards a relationship between PD and atherosclerosis, but the role of TLR2 and TLR4 in the recognition of multiple oral pathogens and their modulation of host response leading to atherosclerosis are not clear.
|
27224005 |
2017 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings indicated that TLR4 Asp299Gly polymorphism may not play a role in AS development.
|
22857799 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, expression of Toll-like receptors in arterial and myocardial cells has been shown and mouse knockout and human studies on polymorphisms point to a role of Toll-like receptor 4 in neointima formation and atherosclerosis.
|
14522407 |
2003 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have demonstrated that toll like receptor 4 (TLR4) is highly expressed in atherosclerotic lesions and participates in the progression of atherosclerosis.
|
27876618 |
2017 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In summary, results in our study do not support the hypothesis that the rs4986790 (+896A>G, rs4986790" genes_norm="7099">Asp299Gly) TLR4 variant may influence predisposition for subclinical atherosclerosis and clinically evident CV disease in RA patients.
|
22360682 |
2012 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, further subgroup analyses revealed that TLR4 rs1927911 polymorphism was significantly associated with the risk of cerebral infarction in the recessive model (95% CI 0.46-0.96), whereas TLR4 rs4986791 polymorphism was significantly correlated with susceptibility to atherosclerosis among Asians in the dominant (95% CI 1.58-6.66), additive (95% CI 0.13-0.69) and allele (95% CI 1.58-5.53) models.
|
28474755 |
2017 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A recent study has also indicated that TLR4 gene variation influences the effect of statin treatment on reducing atherosclerosis complications.
|
15864121 |
2005 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Atorvastatin and/or probucol suppresses ER stress and increase the level of TLR-4, which lowers NF-κB, resulting in the recovery of atherosclerosis in the ApoE<sup>-/-</sup> mouse model.
|
30551396 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD-14, MMP-3, ABCA1, Toll-like receptor-4 (TLR-4), lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), arachidonate lipoxygenase-15 (ALOX-15), and Connexin37 polymorphisms and macrophage dysfunction signify their importance in atherosclerosis.
|
18000963 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
β2-glycoprotein I/anti-β2-glycoprotein I antibody complex (β2/aβ2) could promote oxLDL-induced endothelial inflammation through Toll-like receptor 4 (TLR4), therefore accelerates atherosclerosis in patients with anti-phospholipid syndrome (APS).
|
31654747 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibrinogen has been implicated in atherosclerosis; in part by activating the lipopolysaccharide (LPS) receptor Toll-like receptor 4 (TLR4).
|
18690351 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that palmitate-induced apoptosis depends on the activation of the TLR4/ROS/p53 signaling pathway, and that TLR4 may be a potential therapeutic target for the prevention and treatment of atherosclerosis.
|
28609685 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine the effects on TLR4 activation of two reactive oxidized lipids carried by oxidized low-density lipoproteins, the oxysterol 27-hydroxycholesterol (27-OH) and the aldehyde 4-hydroxynonenal (HNE), both of which accumulate in atherosclerotic plaques and play a key role in the pathogenesis of atherosclerosis.
|
25757594 |
2015 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because BEP-CE is present in human plasma and human atherosclerotic lesions, BEP-CE-induced and TLR4/SYK-mediated macrophage responses may contribute to chronic inflammation in human atherosclerosis.
|
24376657 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although Toll-like receptor 4 (TLR-4) is involved in monocyte activation in patients with accelerated forms of atherosclerosis, the relationship between the expression of TLR-4 on circulating monocytes and coronary plaque vulnerability has not previously been evaluated.
|
28344199 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, recent data now directly implicate signaling by TLR4 in the pathogenesis of atherosclerosis, establishing a key link between atherosclerosis and defense against both foreign pathogens and endogenously generated inflammatory ligands.
|
15528321 |
2004 |